Cephalosporinase

Also Known As:

Cephalexin Amidase; Cephalosporin Amido-beta-Lactam Hydrolase; Cephalosporin beta-Lactamase; Amidase, Cephalexin; Amido-beta-Lactam Hydrolase, Cephalosporin; Cephalosporin Amido beta Lactam Hydrolase; Cephalosporin beta Lactamase; Hydrolase, Cephalosporin Amido-beta-Lactam; beta Lactamase II; beta-Lactamase, Cephalosporin; beta-Lactamase II

Networked: 42 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Amidohydrolases: 43
      - beta-Lactamases: 2628
        Cephalosporinase: 42
        E coli CMY-13 cephalosporinase
        E coli CMY-9 protein
        E coli DHA-1 cephalosporinase
        PPM-1 beta-lactamase

Experts

1.	Mimoz, Olivier: 3 articles (06/2013 - 01/2012)
2.	Poirel, Laurent: 2 articles (03/2021 - 05/2012)
3.	Juan, Carlos: 2 articles (01/2021 - 05/2006)
4.	Oliver, Antonio: 2 articles (01/2021 - 05/2006)
5.	Jacolot, Anne: 2 articles (06/2013 - 01/2012)
6.	Judel, Claire: 2 articles (06/2013 - 01/2012)
7.	Louchahi, Kamel: 2 articles (06/2013 - 01/2012)
8.	Marchand, Sandrine: 2 articles (06/2013 - 01/2012)
9.	Petitjean, Olivier: 2 articles (06/2013 - 01/2012)
10.	Barchiesi, Francesco: 1 article (02/2022)

Related Diseases

1.	Pneumonia (Pneumonitis) 01/01/2012 - "Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae." 06/01/2013 - "How to solve the problem of spontaneous bacterial clearance when testing new antibiotic treatment: results on experimental pneumonia due to a derepressed cephalosporinase-producing Enterobacter cloacae." 01/01/2012 - "The aim of this study was to compare the bactericidal activity of cefepime plus amikacin against experimental pneumonia induced by a stably derepressed cephalosporinase-producing Enterobacter cloacae strain in immunocompetent and leucopenic rats. " 01/01/2021 - "WCK 4282 (cefepime 2 g-tazobactam 2 g) maximizes systemic exposure of tazobactam and restores cefepime activity against various extended-spectrum β-lactamase (ESBL)- and cephalosporinase-producing strains in vitro We describe clinical WCK 4282 exposure efficacies against various serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa isolates in a murine pneumonia model. " 12/01/1998 - "The antibacterial activities of human regimens of cefepime, ceftazidime, and imipenem alone or in combination with amikacin against an isogenic pair of Enterobacter cloacae strains (wild type and its corresponding derepressed cephalosporinase mutant) were compared by using our nonlethal model of pneumonia with 180 immunocompetent rats. "
2.	Cross Infection (Nosocomial Infection) 01/01/2021 - "Pseudomonas aeruginosa, a major cause of nosocomial infections, is considered a paradigm of antimicrobial resistance, largely due to hyperproduction of chromosomal cephalosporinase AmpC. " 04/01/1996 - "The increasing prevalence of stable derepressed mutants over-producers of type I chromosomal cephalosporinase in inducible Enterobacteriaceae and Pseudomonas aeruginosa challenges the adequacy of third generation cephalosporins in the empirical treatment of certain nosocomial infections. " 05/01/1996 - "Nosocomial infections encountered in intensive care units are frequently due to Gram negative bacilli among which Stenotrophomonas maltophilia, Acinetobacter sp., and Enterobacter sp. The aim of the present study was to evaluate the in vitro bactericidal activity of the new broad spectrum cephalosporins cefepime (FEP) and cefpirome (CPO) alone or in combination with amikacin (AKN), gentamicin (GTN) or ciprofloxacin (CIP) against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae producing a derepressed cephalosporinase. "
3.	Infections 01/01/2020 - "The identification of mutants that sensitize UPEC to cefotaxime, despite the presence of a cephalosporinase, provides a framework for the development of new approaches to treat infections caused by MDR pathogens." 12/14/2015 - "Emergence of OXA-162 Carbapenemase- and DHA-1 AmpC Cephalosporinase-Producing Sequence Type 11 Klebsiella pneumoniae Causing Community-Onset Infection in Greece." 11/01/2014 - "The Gram-negative pathogenic bacteria Klebsiella oxytoca and Klebsiella pneumoniae produce the extended spectrum β-lactamase (ESBL) and cephalosporinase enzymes and are the major causes of hospital acquired (HA) infections and epidemics in non-hygienic communities in the majority of developing countries. " 05/01/2012 - "Therefore, ceftazidime may be recommended for the treatment of infections due to OXA-48 producers if they do not coproduce an extended-spectrum β-lactamase or a plasmid-mediated AmpC cephalosporinase." 09/01/1997 - "However, all isolates responsible for this type of infection at the University Hospital of Nancy from 1990 to 1994 (24 strains isolated from 22 patients presented an identical antibiotype with especially a natural resistance phenotype to beta-lactam antibiotics except one cephalosporinase-over-producing strain. "
4.	Urinary Tract Infections (Urinary Tract Infection) 09/01/2012 - "Describe the presence of CTX-M-1 phylogenetic subgroup extended-spectrum β-lactamases (ESBL), associated with TEM and SHV genes, and the gene encoding cephalosporinase, CMY-2 in Escherichia coli and Klebsiella pneumoniae isolates from community-acquired urinary tract infections. " 02/28/2022 - "Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. " 09/01/1983 - "However, in a clinical trial of BRL 25000 (amoxicillin-clavulanic acid), excellent results were obtained in complicated urinary tract infections caused by Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii strains which produced cephalosporinase and were highly resistant to amoxicillin alone. " 01/01/2021 - "Ceftolozane-tazobactam (C/T) is a new fifth-generation cephalosporin/beta-lactamase inhibitor combination approved by the Food and Drug Administration and the European Medicines Agency for treatment of complicated intraabdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia in adult patients. "
5.	Cystic Fibrosis (Mucoviscidosis) 10/26/2022 - "Longitudinal Evolution of the Pseudomonas-Derived Cephalosporinase (PDC) Structure and Activity in a Cystic Fibrosis Patient Treated with β-Lactams." 11/01/2018 - "Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis." 06/01/2014 - "Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients." 06/01/2000 - "Among cystic fibrosis strains, resistance to beta-lactam antibiotics was mainly due to overproduction of the constitutive cephalosporinase (18.6%), whereas production of a transferable beta-lactamase was rare (1.4%). "

Related Drugs and Biologics

1.	Cefepime (Maxipime)
2.	Amikacin (A.M.K)
3.	Cephalosporins (Cephalosporin Antibiotics)
4.	Polytetrafluoroethylene (Teflon)
5.	Gentamicins (Gentamicin)
6.	Ciprofloxacin (Cipro)
7.	Cefpirome (HR 810)
8.	beta-Lactamases (beta-Lactamase)
9.	Enzymes
10.	beta Lactam Antibiotics

Related Therapies and Procedures

1.	Therapeutics